Affinor Growers US-Partner Herbal Analytics Signs Exclusive 2-Year Service Agreement With MediGrow

MONTREAL, QUEBEC--(Marketwired - March 18, 2015) - Affinor Growers Inc. (CSE:AFI)(OTCQB:RSSFF)(FRANKFURT:1AF) ("Affinor" or the "Corporation), a diversified agriculture and biotechnology company with proprietary vertical farming systems, is pleased to announce that it's Washington State testing laboratory, Herbal Analytics, has signed an exclusive service agreement with MediGrow (Washington State RCW 59.61^ª)

MediGrow (www.medigrowproducts.com) is in the final approval stages with the Washington State Liquor Control Board (LCB) for a I-502 licence, necessary for marijuana production. MediGrow will operate in a 10,000 square foot commercial building on 35 acres in Arlington, Washington, with abilities to increase grow capacity to 30,000 square foot in 2016 using greenhouse grow technology. MediGrow, Herbal Analytics and Affinor have combined resources to explore grow methods best used for compound research, clinical trials and product formulations for drug discovery.

Herbal Analytics will provide the following services to MediGrow in accordance with the terms and conditions of the signed agreement beginning April 1st, 2015 until March 31st, 2017:

• Drug discovery research and growing method consulting;
• Quality assurance testing upon LCB approval;
• Bi-weekly condition testing of planted material;
• As needed testing for future crop selection;
• As needed consulting services on data;
• As needed courier service and onsite planning.

As consideration for the services executed by Herbal Analytics, MediGrow will pay the following: 3,000 USD per month for the first six months (April - September 2015), 6,500 USD per month for October 2015 - March 2016 and 11,000 USD per month for April 2016 - March 2017. Extra charges include mainly 325 USD per hour for data consulting billed on a separate invoice and also to be paid monthly.

Nick Brusatore, Affinor Chairman, comments: "We are very pleased with this constant cashflow agreement and we are continuing negotiations for further contracts in that sector".

Affinor owns a 49% stake of Herbal Analytics, a full service analytical and consulting laboratory for botanical quality testing and natural product drug development. They are becoming a leader in the industry for guided intelligence in product development and safety testing for medical and recreational Cannabis products in Washington State.

Herbal Analytics (www.herbalanalytics.com) has extensive herbal product industry experience with an edge using the most efficient and innovative analytical platforms for accurate and rapid results. Herbal Analytics chemical tests have been legitimized and proven, based on Bio Analytical Method Validation for accuracy and precision.

About Affinor Growers Inc.

Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol ("AFI"). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries and high quality medical Marijuana. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.

On Behalf of the Board of Directors

AFFINOR GROWERS INC.

Sebastien Plouffe, President & CEO

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING INFORMATION

This News Release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This News Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.